Chronic effects of FR139317 and enalapril on renal failure rats with moderate exercise.

Abstract:

:We assessed the renal effects of moderate treadmill exercise in the spontaneously hypertensive rats (SHR) remnant kidney model of chronic renal failure (CRF). The effects of chronic administration of a specific endothelin (ET) subtype A (ETA) receptor antagonist, FR139317 (32 mg/kg/day i.p.) and an angiotensin-converting enzyme inhibitor, enalapril (2 mg/kg/day i.p.), in combination with moderate exercise were also investigated. Eight-week-old SHR were subjected to 5/6 nephrectomy. One week after surgery the rats were divided into five groups: (a) no treadmill running; (b) moderate treadmill running, 20 m/min for 60 min (Ex) per day; (c) Ex plus FR139317; (d) Ex plus enalapril; and (e) m-Ex plus enalapril in combination with FR139317, for 4 weeks. In SHR-CRF, Ex significantly attenuated the increase in urinary protein excretion. Enalapril significantly attenuated the increase in systolic blood pressure and urinary protein excretion. FR139317 at this dose did not show any antihypertensive or renal protective effect in this model. These results suggest that moderate exercise may protect renal function in SHR CRF. They also suggest that FR139317 may not have an additional antihypertensive and renal protective effect in this exercise model.

journal_name

J Cardiovasc Pharmacol

authors

Kohzuki M,Kamimoto M,Wu XM,Yoshida K,Saito T,Sato T

doi

10.1097/00005344-199800001-00139

subject

Has Abstract

pub_date

1998-01-01 00:00:00

pages

S486-8

eissn

0160-2446

issn

1533-4023

journal_volume

31 Suppl 1

pub_type

杂志文章
  • Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation.

    abstract::Atherosclerosis, like several other vascular diseases, exhibits structural and functional abnormalities resulting partially from an exaggerated proliferation of vascular smooth-muscle cells (VSMCs). Ca2+ channel blockers, such as amlodipine, have been suggested to retard or even prevent the progression of atherosclero...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199805000-00019

    authors: Stepien O,Gogusev J,Zhu DL,Iouzalen L,Herembert T,Drueke TB,Marche P

    更新日期:1998-05-01 00:00:00

  • Cardioprotection by streptozotocin-induced diabetes and insulin against ischemia/reperfusion injury in rats.

    abstract::The effects of streptozotocin (STZ)-induced diabetes (DM) and insulin on cardiac performance were investigated during reperfusion after low-flow ischemia in rats. Hearts were isolated 4 weeks after intravenous injection of STZ (65 mg/kg) or vehicle and retrogradely perfused in the presence (throughout the perfusion pe...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200210000-00001

    authors: Nawata T,Takahashi N,Ooie T,Kaneda K,Saikawa T,Sakata T

    更新日期:2002-10-01 00:00:00

  • Diet and the role of lipoproteins, lipases, and thyroid hormones in coronary lesion growth.

    abstract::Relationships between lipoprotein fractions, lipoprotein lipase activities, thyroid hormones, and coronary lesion growth were studied among 35 male patients with severe coronary atherosclerosis, who had participated in the Leiden Intervention Trial, a lipid-lowering dietary intervention program. Coronary arteriography...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Barth JD,Jansen H,Kromhout D,Reiber JH,Birkenhäger JC,Arntzenius AC

    更新日期:1987-01-01 00:00:00

  • Calcium antagonists and vascular smooth muscle cells in atherogenesis.

    abstract::Vascular smooth muscle cells (SMCs) play a key role in the development of atherosclerotic lesions. Vascular smooth muscle, however, does not represent a homogeneous tissue. Using myosin as a marker of the differentiation processes in development and in vascular disease, we have been able to demonstrate the existence o...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00005344-199219002-00004

    authors: Pauletto P,Sartore S,Giuriato L,Scatena M,Tonello M,Scannapieco G,Pessina AC,Dal Palù C

    更新日期:1992-01-01 00:00:00

  • Role of adenosine in vasodilation of epimyocardial coronary microvessels during reduction in perfusion pressure.

    abstract::Previous studies in which an isolated heart or in situ constant pressure preparation was used suggested a minimal role for adenosine in autoregulatory control of coronary circulation. These results, however, are controversial, and the role of adenosine in autoregulation of flow in heart is uncertain. To test the hypot...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199409000-00012

    authors: Komaru T,Lamping KG,Dellsperger KC

    更新日期:1994-09-01 00:00:00

  • The emerging role of ACE inhibitors in the treatment of cardiovascular disease.

    abstract::Large clinical studies have established the therapeutic benefit of angiotensin-converting enzyme (ACE) inhibitors in the treatment of hypertension and chronic congestive heart failure (CHF). In patients with hypertension, ACE inhibitors have been shown to lower blood pressure, with an excellent safety profile. They ma...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00005344-199000152-00002

    authors: Zannad F

    更新日期:1990-01-01 00:00:00

  • Pediatric cardiovascular drug development and research: integration of modeling and simulation as one future direction.

    abstract::The integration of the needs of children into the legal drug development process since 1997 in the United States and since 2007 in the European Union has improved health and stimulated innovative approaches in the design of clinical trials and will benefit both current and future populations. According to the US Food ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/FJC.0b013e31822233c1

    authors: Läer S

    更新日期:2011-09-01 00:00:00

  • Vascular endothelium and Ca2+ antagonists.

    abstract::Endothelial cells can release both relaxing and contracting factors. Since the release of endothelium-dependent relaxing factor is prevented by incubation in Ca2+-free solution and can be triggered by the Ca2+ ionophore A 23187, it must require an increase in cytoplasmic Ca2+ concentration in the endothelial cells. Ca...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00005344-198812006-00007

    authors: Vanhoutte PM

    更新日期:1988-01-01 00:00:00

  • Prostacyclins are only weak antagonists of coronary vasospasm induced by authentic thromboxane A2 and serotonin.

    abstract::The actions of prostacyclin and its synthetic analog iloprost on the release and action of platelet-derived serotonin (5-HT) and thromboxane (TX) A2 were studied in vitro. Washed human platelet suspensions (WPS) (4 X 10(8) platelets/ml) were stimulated with arachidonic acid (AA) (30 mumol/L) and the incubate transferr...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198605000-00025

    authors: Schrör K,Verheggen R

    更新日期:1986-05-01 00:00:00

  • The renin-angiotensin system and its receptors.

    abstract::The renin-angiotensin system (RAS) plays an important role in blood pressure control and in water and salt homeostasis. It is involved in the pathophysiology of hypertension and structural alterations of the vasculature, kidney, and heart, including neointima formation, nephrosclerosis, postinfarction remodeling, and ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00005344-199900001-00005

    authors: Stroth U,Unger T

    更新日期:1999-01-01 00:00:00

  • Effects of endothelin-1 in isolated perfused rat heart.

    abstract::We examined the effects of the vasoconstrictor peptide endothelin-1 in the isolated heart and defined interactions of endothelin-1 with other hormone systems. Isolated isovolumic rat hearts were perfused with Krebs-Henseleit buffer at constant pressure. First, the effect of a single bolus of endothelin-1 (4-400 pmol) ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199007000-00001

    authors: Neubauer S,Ertl G,Haas U,Pulzer F,Kochsiek K

    更新日期:1990-07-01 00:00:00

  • Comparison between the effects of MDL 72567 and nifedipine on various cardiovascular parameters in conscious sinoaortic-denervated rats and sham-operated controls.

    abstract::In this study the effects of a new calcium entry blocking agent, 2,6-dimethyl-3-methoxycarbonyl-4-(2-nitrophenyl)-5-(2-furoyl)-1, 4-dihydropyridine (MDL 72567), were compared with those of nifedipine on blood pressure, heart rate, ECG, and cardiac contractility indices in conscious sinoaortic baroreceptor-denervated (...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198710000-00012

    authors: Petty MA,Spedding M,Di Francesco GF

    更新日期:1987-10-01 00:00:00

  • Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.

    abstract::Vasopeptidase inhibitors are single molecules that inhibit neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE) simultaneously. Omapatrilat, the first in this new class of cardiovascular agents, potentiates vasodilatory and cardioprotective peptides and represses angiotensin II. This study compared the ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199912000-00003

    authors: Trippodo NC,Fox M,Monticello TM,Panchal BC,Asaad MM

    更新日期:1999-12-01 00:00:00

  • A double-blind comparison of amlodipine and placebo added to open enalapril in patients with moderate to severe essential hypertension.

    abstract::The antihypertensive efficacy and tolerability of amlodipine in combination with enalapril were assessed in this two-center study. Patients with moderate to severe hypertension and with diastolic blood pressure > 95 mm Hg after 4 weeks of treatment with open-label enalapril 5-10 mg daily were randomized to receive aml...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/00005344-199117001-00006

    authors: Davies J,Jensen H,Garsdal P

    更新日期:1991-01-01 00:00:00

  • The effect of adenosine on blood pressure variability in sinoaortic denervated rats is mediated by adenosine A2a-Receptor.

    abstract::It is known that adenosine decreases blood pressure (BP) level as well as blood pressure variability (BPV). However, there is little information about the effect of adenosine on BPV. With a computerized analytic system for BP and heart rate (HR) that could sample the data continuously in conscious, freely moving rats,...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200011000-00019

    authors: Shen FM,Su DF

    更新日期:2000-11-01 00:00:00

  • Prostacyclin does not inhibit rho-kinase: an implication for the treatment of pulmonary hypertension.

    abstract::Primary pulmonary hypertension continues to be a fatal disease. We have recently demonstrated that long-term inhibition of Rho-kinase, an effector of the small GTPase Rho, is effective for the treatment of pulmonary hypertension (PH) in rats and humans. Prostacyclin has been clinically used for the treatment of PH wit...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/01.fjc.0000151898.65260.6a

    authors: Abe K,Morikawa K,Hizume T,Uwatoku T,Oi K,Seto M,Ikegaki I,Asano T,Kaibuchi K,Shimokawa H

    更新日期:2005-02-01 00:00:00

  • Enhancement of ouabain arrhythmias by fatty acids.

    abstract::Possible enhancement by free fatty acids (FFA) of the arrhythmogenic actions of ouabain was studied in rabbits. The mean dose of ouabain required for inducing ventricular tachycardia or fibrillation in conscious animals was significantly lowered by intravenous injection of 5 ml of a 20% fat emulsion (Lipofundin), whic...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198005000-00010

    authors: Sánchez-Serrano D,Alvarez JL,García-Barreto D

    更新日期:1980-01-01 00:00:00

  • CGP 41251, a new potential anticancer drug, improves contractility of rat isolated cardiac muscle subjected to hypoxia.

    abstract::The aim of the present work was to examine the effects of 4'-N-benzoyl staurosporine (CGP 41251), a protein kinase C inhibitor with broad antiproliferative activity in many cell lines, on the rat isolated heart contractility under normoxic and hypoxic conditions. Additionally, we examined the effects of CGP 41251, WB-...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200106000-00011

    authors: Kocic I,Dworakowska D,Dworakowski R,Petrusewicz J

    更新日期:2001-06-01 00:00:00

  • Response of peripheral collateral arteries in the dog to prostaglandins E1, E2, F2 alpha, and I2 (prostacyclin).

    abstract::Prostaglandins (PG) E2, E2, E2 alpha, and I2 [prostacyclin (PGI2)] were tested in vitro on collateral arteries that enlarge following chronic occlusion of the femoral artery in the dog. After contraction with an ED50 dose of KCl, serial doses of a PG were added. Collateral arteries relaxed significantly to PGI2 (10(-7...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198209000-00014

    authors: Williams PB,Joyner JH

    更新日期:1982-09-01 00:00:00

  • Efficacy of carvedilol in exercise-induced myocardial ischemia.

    abstract::The exercise response to a single oral dose (25 mg) of a new beta-blocking agent that also has potent vasodilating properties, carvedilol, was assessed in 15 patients with stable exertional angina, positive exercise tests (greater than or equal to 1 mm ST depression) and coronary artery disease. A placebo-controlled, ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Kaski JC,Rodriguez-Plaza L,Brown J,Maseri A

    更新日期:1987-01-01 00:00:00

  • Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease.

    abstract::Tetrahydrobiopterin is the reduced unconjugated pterin that serves as an essential cofactor for the normal enzymatic function of the aromatic amino acid hydroxylases and for the nitric oxide synthases (NOS). Its role in the latter biochemistry is being increasing appreciated, as depletion or oxidation of BH4 results i...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/FJC.0b013e318123f854

    authors: Moens AL,Kass DA

    更新日期:2007-09-01 00:00:00

  • Nitrendipine reverses vasoconstriction and renal hemodynamic changes in experimental hypertension.

    abstract::Nitrendipine, a calcium entry blocker, was administered by gavage (3 mg/100 g body weight/day) to rats with prolonged angiotensin-II-(AII) induced hypertension. AII was infused by osmotic minipump implanted subcutaneously. Persistent hypertension was established after 5 days. Normotensive control rats had empty sham p...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Sterzel RB,Huelsemann JL,McKenzie DE,Wilcox CS

    更新日期:1984-01-01 00:00:00

  • Differential changes in lymphocyte beta 2-adrenoceptor density by beta-blocker administration: role of intrinsic sympathomimetic activity.

    abstract::To study the role of intrinsic sympathomimetic activity (ISA) in beta-blocker-induced changes of beta-adrenoceptors, the effects of administration of several beta-blockers for 9 days on lymphocyte beta 2-adrenoceptor density--assessed by 125iodocyanopindolol binding--were investigated in 47 normotensive volunteers. Pr...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Daul A,Wang XL,Borchard U,Bock KD,Brodde OE

    更新日期:1986-01-01 00:00:00

  • The efficacy and tolerability of azilsartan in mice with left ventricular pressure overload or acute myocardial infarction.

    abstract::Angiotensin II receptor blockers (ARBs) are used for the treatment of patients with heart failure and hypertension. Yet their safety has been questioned by some who observed delayed cardiac healing and scar thinning after myocardial infarction (MI). To clarify potential efficacy and safety of ARBs, we administered Azi...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0b013e318288a6d7

    authors: Quinn Baumann P,Zaman AK,McElroy-Yaggy K,Sobel BE

    更新日期:2013-05-01 00:00:00

  • Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.

    abstract:BACKGROUND:Telmisartan is an angiotensin II receptor blocker, which acts as a partial agonist of peroxisome proliferator activator receptor-γ (PPAR-γ). Because PPAR-γ initiates a variety of antiinflammatory responses, the effect on myocardial ischemia is to be elucidated. METHODS AND RESULTS:The left anterior descendi...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0b013e3182592d7b

    authors: Nagashima A,Watanabe R,Ogawa M,Suzuki J,Masumura M,Hishikari K,Shimizu T,Takayama K,Hirata Y,Nagai R,Isobe M

    更新日期:2012-08-01 00:00:00

  • Desmodium gangeticum (Linn.) DC. exhibits antihypertrophic effect in isoproterenol-induced cardiomyoblasts via amelioration of oxidative stress and mitochondrial alterations.

    abstract::Cardiac hypertrophy occurs in response to increased workload, such as hypertension or valvular heart disease. Oxidative stress has been implicated in cardiac hypertrophy and in its transition to heart failure. This study was taken up with the objective to evaluate the role of oxidative stress in cardiomyoblast hypertr...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0b013e3182756ad3

    authors: Sankar V,Pangayarselvi B,Prathapan A,Raghu KG

    更新日期:2013-01-01 00:00:00

  • Influence of ketanserin on regional myocardial blood flow after myocardial infarction in baboons.

    abstract::Serotonin (5-hydroxytryptamine, 5-HT) mediates vasoconstriction and vasodilation in normal coronary circulation of various animal species. In the presence of coronary artery disease, serotonin may inhibit coronary collateral formation and stimulate predominantly vasoconstriction. We tested the effect of ketanserin, a ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199301000-00021

    authors: Hartford CG,Rogers GG,Marcos EF,Rosendorff C

    更新日期:1993-01-01 00:00:00

  • A circulating sodium transport inhibitor and essential hypertension.

    abstract::Evidence for the hypothesis that the rise in peripheral resistance that occurs in inherited hypertension is due largely to the observed rise in the circulating level of a sodium transport inhibitor is reviewed. A sequence of events is proposed linking a postulated genetic defect in the kidney's ability to excrete sodi...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00005344-198400061-00012

    authors: MacGregor GA,de Wardener HE

    更新日期:1984-01-01 00:00:00

  • Renin-angiotensin system inhibitors prevent the recurrence of atrial fibrillation: a meta-analysis of randomized controlled trials.

    abstract:OBJECTIVE:This study was designed to assess whether angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could prevent the recurrence of atrial fibrillation (AF). METHODS:A systemic literature search of PubMed, EMBASE, and Cochrane Controlled Trials Register till 2012 was performed...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/FJC.0b013e3182a094a1

    authors: Han M,Zhang Y,Sun S,Wang Z,Wang J,Xie X,Gao M,Yin X,Hou Y

    更新日期:2013-10-01 00:00:00

  • Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.

    abstract::Nineteen hypertensive patients were treated with increasing doses of the new angiotensin-converting enzyme inhibitor MK 421. Twenty milligrams orally reduced blood pressure from 180/112 +/- 6.8/3.6 (mean +/- SEM) to 160/100 +/- 6.5/3.3 mm Hg (p less than 0.005) while heart rate increased from 75 +/- 2 to 87 +/- 3 beat...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Biollaz J,Brunner HR,Gavras I,Waeber B,Gavras H

    更新日期:1982-11-01 00:00:00